We hope this sourcebook gives you some practical guidance on core principles and some key areas of compliance; and where to go for more advice when working together with patients and patient organisations.

Whilst this sourcebook provides informal guidance, it remains the responsibility of companies to ensure that they comply with the most up-to-date version of the ABPI Code. Ways of working together between pharmaceutical companies and patient organisations continue to develop.

We aim to update the sourcebook on a regular basis with information and pointers to guidance, as well as any changes to the ABPI Code.

We would appreciate any comments and feedback on this sourcebook to feed into future editions.


We would like to thank the following organisations for their help and contributions in developing this guidance:

  • AbbVie
  • Alexion,
  • AstraZeneca Rare Disease
  • Astellas
  • Bayer
  • Boehringer Ingelheim Ltd
  • Gilead
  • Janssen
  • Lilly
  • MSD
  • Napp
  • Novo Nordisk
  • Pfizer
  • Takeda
  • TEVA
  • UCB
  • Action Kidney Cancer
  • AMRC
  • Asthma + Lung UK
  • Cancer 52
  • Cystic Fibrosis Trust
  • Diabetes UK
  • UK Gout Society
  • The Haemophilia Society
  • Kidney Research UK
  • MPS Society
  • National Voices
  • NCRI
  • NIHR
  • Pain UK
  • Parkinsons UK
  • Primary Care Rheumatology and Musculoskeletal Medicines Society
  • Versus Arthritis

Last modified: 20 September 2023

Last reviewed: 20 September 2023